The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as ...

The new vaccine, mNexspike (mRNA-1283), is a step toward next-generation coronavirus vaccines. It’s made in a way that allows for a lower dose, a fifth of the dose of its current COVID-19 vaccine, Spi ...

GOP Rep. Marjorie Taylor Greene of Georgia, an outspoken COVID-19 vaccine critic, blasted the FDA's green lighting of the mNEXSPIKE as "Not MAHA at all!!!" in a tweet ...

The FDA has approved a new COVID-19 vaccine developed by Moderna, offering a lower-dose option aimed at older adults and people with underlying health risks. The vaccine, named mNexspike, is part ...

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...

"MNEXSPIKE is approved for use in individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years of age and older, or 12 years through 64 years of age with at least one ...

mNEXSPIKE is a vaccine to protect against COVID-19. mNEXSPIKE is for people who have received a COVID-19 vaccine before and are: 65 years of age and older, or 12 years through 64 years of age at ...

The company said it expects to have the vaccine, called mNEXSPIKE, available for the 2025-2026 respiratory virus season. 4 The FDA has approved Moderna’s next-generation COVID-19 vaccine for ...

Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved efficacy and safety profile.

“The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from Covid-19,” Moderna CEO Stéphane Bancel said in the ...

mNEXSPIKE is a vaccine to protect against COVID-19. mNEXSPIKE is for people who have received a COVID-19 vaccine before and are: • 65 years of age and older, or • 12 years through 64 years of ...